KRAS and BRAF mutation status in patients with sporadic colorectal cancer: Data from two different mediterranean countries

International Journal of Biological Markers

Volumn 26, Issue 4, 2011, Pages 276-277

  Symvoulakis, Emmanouil K ^a   Zaravinos, Apostolos ^a   Zoras, Odysseas ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; BRAF GENE; CODON; COLORECTAL CANCER; EXON; GENE; GENE MUTATION; GREECE; HUMAN; LETTER; MOROCCO; MULTICENTER STUDY; ONCOGENE K RAS;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS;

EID: 84555205733     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8874     Document Type: Letter

References (6)

1. Bennani B, Gilles S, Fina F, et al. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. Int J Biol Markers 2010; 25: 179-84.
2. Symvoulakis EK, Zaravinos A, Panutsopulos D, et al. Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers 2007; 22: 12-8.
3. Saridaki Z, Tzardi M, Papadaki C, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011; 6: e15980.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
5. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
6. Lionis C, Symvoulakis EK, Vardavas CI. Implementing family practice research in countries with limited resources: a stepwise model experienced in Crete, Greece. Fam Pract 2010; 27: 48-54.